U.S. markets closed

AVEO Pharmaceuticals, Inc. (AVEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
14.87+0.01 (+0.07%)
At close: 01:00PM EST
14.86 -0.01 (-0.07%)
After hours: 02:25PM EST

AVEO Pharmaceuticals, Inc.

30 Winter Street
Boston, MA 02108
United States
857 400 0101

Full Time Employees114

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael P. BaileyCEO, Pres & Director967.12kN/A1965
Mr. Erick J. Lucera CFA, CPAChief Financial Officer524.21kN/A1968
Mr. Michael FerraressoChief Commercial Officer531.55kN/A1974
Mr. Jeb LedellChief Operating OfficerN/AN/AN/A
Dr. Emile Farhan Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Ms. Danielle HollandVP of Legal & Corp. Sec.N/AN/AN/A
Mr. Kevin PeacockSr. VP of MarketingN/AN/AN/A
Mr. David CristVP of SalesN/AN/AN/A
Ms. Catherine DeRoseVP of HRN/AN/AN/A
Ms. Lisa M. BruneauVP of Fin. & TreasurerN/AN/A1967
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Corporate Governance

AVEO Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.